Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)

    • 21:00 - 23:59
    • 8/06/2022
    • Location: On-Demand
    • Not for CME Credit
    • Type: Workshop
    • Track: N/A
    • +

      WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

      23:22 - 23:23  |  Presenter: Jun Zhao

      • Abstract

      Loading...

  • +

    OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment

    • 12:00 - 13:00
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Locally Advanced Non-small Cell Lung Cancer
    • +

      OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

      12:22 - 12:32  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

      14:52 - 15:02  |  Presenter: Michael Thomas

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

      Presenter: Jun Zhao

      • Abstract

      Loading...

    • +

      EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

      Presenter: Jun Zhao

      • Abstract

      Loading...

    • +

      EP08.01-082 - Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study

      Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC

      Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      EP08.02-136 - Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer

      Presenter: Juan Shen

      • Abstract

      Loading...